Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease

General Information

Summary This study will evaluate the safety and efficacy of intracerebral transplantation of human embryonic stem cells-derived neural precursor cells in patients with Parkinson's Disease.
Description This study is a Phase I/II, open-label, non randomized clinical trial. The study will enroll 50 patients for cell injection, administering a single dose of neural precursor cells by stereotaxic intra-striatal injection.
Clinical trials phase Phases 1/2
Start date (estimated) 2017-05-01
End date (estimated) 2020-12-31
Clinical feature
Label Parkinson's Disease
Link http://purl.obolibrary.org/obo/NCIT_C26845
Description A progressive degenerative disorder of the central nervous system characterized by loss of dopamine producing neurons in the substantia nigra and the presence of Lewy bodies in the substantia nigra and locus coeruleus. Signs and symptoms include tremor which is most pronounced during rest, muscle rigidity, slowing of the voluntary movements, a tendency to fall back, and a mask-like facial expression.
Publications

Administrative Information

NCT number NCT03119636
ICTRP weblink http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT03119636
Other study identifiers
Name ChineseASZQ-003
Source weblink https://clinicaltrials.gov/show/NCT03119636
Regulatory body approval
Name National Health Commission of the PRC;National medical products administration
Country
China
Approval number CMR-20161213-1001
Study sites
Public contact
Email wangliu@ioz.ac.cn
Public email wangliu@ioz.ac.cn
First name Liu
Last name Wang
Country
China
Sponsors Chinese Academy of Sciences
Collaborators

Cell Line

Recruitment

Recruitment Status Recruiting
Estimated number of participants 50
Contact institutions/departments